Applications

1695 – Procedures for the implantation and refill-exchange of the Port Delivery System with ranibizumab to treat neovascular age-related macular degeneration

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation Not applicable
  • Pre-MSAC consultation Closed
  • Outcome Deferred

Application details

Reason for application

New MBS item.

Service or technology in this application

An ocular implant is surgically implanted at the pars plana. Prior to implantation, the ocular implant is filled with Susvimo®, a customised form of ranibizumab. Once filled and implanted, the implant is designed to be permanent and provide continuous release of ranibizumab over an extended period of time. Patients will attend a consultation to have their ocular implant refilled every six months.

Type: Co-dependent technology

Medical condition this application addresses

Age related macular degeneration (AMD) is a chronic eye disease characterised by progressive degenerative abnormalities in the central retina (macula) and is the leading cause of severe vision loss and legal blindness in people over the age of 65 years. Neovascular AMD occurs in around 10-15% of overall AMD cases, and is characterised by choroidal neovascularisation, a process in which new blood vessels grow beneath the retina and macula. In neovascular AMD, the protein vascular endothelial growth factor is predominantly responsible for the abnormal growth of blood vessels and fluid leakage under the retina.

Consultation survey and deadlines

  • PASC consultation: Not applicable
  • MSAC consultation: Closed 11 February 2022

Meetings to consider this application

  • PASC meeting: Bypassing PASC
  • ESC meeting: Bypassing ESC
  • MSAC meeting: 31 March – 1 April 2022